RBC Capital Maintains Edwards Lifesciences(EW.US) With Buy Rating, Cuts Target Price to $85
RBC Capital Reaffirms Their Buy Rating on Edwards Lifesciences (EW)
Daiwa Securities Upgrades Edwards Lifesciences Outperform From Neutral, Adjusts Price Target to $72 From $87
Citi Maintains Edwards Lifesciences(EW.US) With Buy Rating
Analysts' Top Healthcare Picks: Edwards Lifesciences (EW), AbbVie (ABBV)
CICC Research Adjusts Price Target on Edwards Lifesciences to $80 From $105, Maintains Outperform Rating
What 22 Analyst Ratings Have To Say About Edwards Lifesciences
Wolfe Research Upgrades Edwards Lifesciences(EW.US) to Hold Rating
Barclays Maintains Overweight on Edwards Lifesciences, Lowers Price Target to $90
Edwards Lifesciences Price Target Cut to $91.00/Share From $107.00 by Goldman Sachs
Edwards Lifesciences Analyst Ratings
Barclays Maintains Edwards Lifesciences(EW.US) With Buy Rating, Cuts Target Price to $90
Barclays Keeps Their Buy Rating on Edwards Lifesciences (EW)
Hold Rating on Edwards Lifesciences Amid TAVR Challenges and Competitive Pressures
Edwards Lifesciences Price Target Cut to $70.00/Share From $100.00 by TD Cowen
Edwards Lifesciences Downgraded at JPM, Truist on Slower Transcatheter Valve Growth
Oppenheimer Maintains Edwards Lifesciences(EW.US) With Buy Rating, Cuts Target Price to $90
UBS Maintains Edwards Lifesciences(EW.US) With Hold Rating, Cuts Target Price to $90
Oppenheimer Adjusts Price Target on Edwards Lifesciences to $90 From $100
Edwards Lifesciences Price Target Cut to $70.00/Share From $102.00 by Baird